BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 15919106)

  • 1. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2).
    So J; Wang FQ; Navari J; Schreher J; Fishman DA
    Gynecol Oncol; 2005 Jun; 97(3):870-8. PubMed ID: 15919106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC).
    Dutta S; Wang FQ; Wu HS; Mukherjee TJ; Fishman DA
    Gynecol Oncol; 2011 Oct; 123(1):129-37. PubMed ID: 21782227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases.
    Wang FQ; So J; Reierstad S; Fishman DA
    Int J Cancer; 2006 Feb; 118(4):879-88. PubMed ID: 16152587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion.
    Wang FQ; Barfield E; Dutta S; Pua T; Fishman DA
    Gynecol Oncol; 2009 Dec; 115(3):414-23. PubMed ID: 19765808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8.
    So J; Navari J; Wang FQ; Fishman DA
    Gynecol Oncol; 2004 Nov; 95(2):314-22. PubMed ID: 15491751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of matrilysin expression by antisense or RNA interference decreases lysophosphatidic acid-induced epithelial ovarian cancer invasion.
    Wang FQ; Smicun Y; Calluzzo N; Fishman DA
    Mol Cancer Res; 2006 Nov; 4(11):831-41. PubMed ID: 17114341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S1P induced changes in epithelial ovarian cancer proteolysis, invasion, and attachment are mediated by Gi and Rac.
    Devine KM; Smicun Y; Hope JM; Fishman DA
    Gynecol Oncol; 2008 Aug; 110(2):237-45. PubMed ID: 18513786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysophosphatidic acid (LPA) effects on endometrial carcinoma in vitro proliferation, invasion, and matrix metalloproteinase activity.
    Wang FQ; Ariztia EV; Boyd LR; Horton FR; Smicun Y; Hetherington JA; Smith PJ; Fishman DA
    Gynecol Oncol; 2010 Apr; 117(1):88-95. PubMed ID: 20056268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MMP-1-PAR1 axis mediates LPA-induced epithelial ovarian cancer (EOC) invasion.
    Wang FQ; Fisher J; Fishman DA
    Gynecol Oncol; 2011 Feb; 120(2):247-55. PubMed ID: 21093894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner.
    Gil OD; Lee C; Ariztia EV; Wang FQ; Smith PJ; Hope JM; Fishman DA
    Gynecol Oncol; 2008 Feb; 108(2):361-9. PubMed ID: 18073130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway.
    Estrella VC; Eder AM; Liu S; Pustilnik TB; Tabassam FH; Claret FX; Gallick GE; Mills GB; Wiener JR
    Int J Oncol; 2007 Aug; 31(2):441-9. PubMed ID: 17611702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion.
    Jeong KJ; Park SY; Cho KH; Sohn JS; Lee J; Kim YK; Kang J; Park CG; Han JW; Lee HY
    Oncogene; 2012 Sep; 31(39):4279-89. PubMed ID: 22249252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.
    Pustilnik TB; Estrella V; Wiener JR; Mao M; Eder A; Watt MA; Bast RC; Mills GB
    Clin Cancer Res; 1999 Nov; 5(11):3704-10. PubMed ID: 10589790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells.
    Do TV; Symowicz JC; Berman DM; Liotta LA; Petricoin EF; Stack MS; Fishman DA
    Mol Cancer Res; 2007 Feb; 5(2):121-31. PubMed ID: 17314270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells.
    Fishman DA; Liu Y; Ellerbroek SM; Stack MS
    Cancer Res; 2001 Apr; 61(7):3194-9. PubMed ID: 11306508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of lysophosphatidic acid receptor-2 expression by RNA interference decreases lysophosphatidic acid-induced urokinase plasminogen activator activation, cell invasion, and migration in ovarian cancer SKOV-3 cells.
    Wang GL; Wen ZQ; Xu WP; Wang ZY; Du XL; Wang F
    Croat Med J; 2008 Apr; 49(2):175-81. PubMed ID: 18461672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion.
    Sengupta S; Kim KS; Berk MP; Oates R; Escobar P; Belinson J; Li W; Lindner DJ; Williams B; Xu Y
    Oncogene; 2007 May; 26(20):2894-901. PubMed ID: 17130843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase.
    Wang FQ; So J; Reierstad S; Fishman DA
    Int J Cancer; 2005 Mar; 114(1):19-31. PubMed ID: 15523695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells.
    Rosanò L; Varmi M; Salani D; Di Castro V; Spinella F; Natali PG; Bagnato A
    Cancer Res; 2001 Nov; 61(22):8340-6. PubMed ID: 11719468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice.
    Li H; Wang D; Zhang H; Kirmani K; Zhao Z; Steinmetz R; Xu Y
    Mol Cancer Ther; 2009 Jun; 8(6):1692-701. PubMed ID: 19509252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.